MedWatch

French reforms and US vaccinations benefit Demant in corona-struck times

Demant's Tuesday upgrade was highly driven by the French market but the firm has also advanced in the rest of the world, and the hearing aid firm's CEO Søren Nielsen is confident that Demant will be able to keep up the pace for the rest of the year.

Demant President & CEO Søren Nielsen | Photo: Kenneth Lysbjerg Koustrup/ERH

Demant has raised its guidance for 2021 based on looking back on the first three months, rather than ahead to the next nine, says Søren Nielsen, CEO of Demant, to MedWatch.

“We are right on track, if not a little ahead of schedule, and that of course gives us reason to believe that our plans for the rest of the year are intact and realistic. Raising our expectations for the year is therefore primarily related to the time that has passed and not a change in terms of what lies ahead of us,” he says.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs